Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Breast cancer with lymphatics - Axel Kock - stock.adobe.com.jpeg

March 5th 2024

Annual Breast Cancer Screening Should Begin at Age 40 Years, Study Finds

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

Doctor comforting a patient | Image credit: lenetsnikolai - stock.adobe.com

March 1st 2024

Treating the Whole Person in Cancer Care: Addressing Comprehensive Services

The session at ACCC's 50th Annual Meeting & Cancer Center Business Summit featured discussions on patient navigation, addressing patients' sexual health, needs of LGBTQ+ patients, and more.

Mila Felder, MD, FACEP

March 1st 2024

Dr Mila Felder Explains Advocate Health's Approach to Well-Being for the Postpandemic Oncology Workforce

Hayden E. Klein

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, talks about tailoring the Stanford Model of Professional Fulfillment to support the postpandemic oncology workforce.

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

March 1st 2024

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Margaret I. Liang, MD, MS Ling Chen, MD, MPH Emeline M. Aviki, MD, MBA Jason D. Wright, MD

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.

February 29th 2024

QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices

ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.

February 29th 2024

What Are the Steps to Quality Improvement in Cancer Care?

Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.

February 26th 2024

What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

Blue folder with Cancer diagnosis | vchalup - stock.adobe.com

February 22nd 2024

COVID-19 Pandemic's Disruption on Cancer Detection in the US

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)

February 16th 2024

Kiana Mehring Discusses the Future of Value-Based Oncology Care

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Breast cancer - Axel Kock - stock.adobe.com.jpeg

February 14th 2024

Breast Cancer Incidence Highest Among Young Black Women in the US

Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.

February 14th 2024

How Real-World Evidence Can Spur Collaboration and Changes in Oncology

Zhaohui Su, PhD

Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin

February 9th 2024

Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist

Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.

February 7th 2024

COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy

Maggie L. Shaw Pearl Steinzor

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.

Blood sample test with positive diagnosis of thrombosis risk in a coagulation test | angellodeco - stock.adobe.com

February 2nd 2024

Risk of Venous Thromboembolism Increases After Cancer Surgery, Study Finds

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Enhertu (trastuzumab deruxtecan) product packaging | AstraZeneca photo

January 30th 2024

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

Dr Lucy Langer

January 28th 2024

Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity

Hayden E. Klein

UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.

Samyukta Mullangi, MD, MBA | Image credit: X

January 22nd 2024

Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program

Hayden E. Klein

The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.

January 16th 2024

First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

Kirollos Hanna | Image credit: LinkedIn

January 15th 2024

Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions

Hayden E. Klein

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.

Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com

January 14th 2024

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.

Pile of dollars and stethoscope | nata777_7 - stock.adobe.com

January 11th 2024

Substantial State Variations Identified in Health Insurance Coverage at Cancer Diagnosis

Health insurance coverage is a strong determinant of cancer care access and survival, and the observed variations are despite a significant increase in coverage under the Affordable Care Act.

Edward Arrowsmith, MD, MPH

January 10th 2024

How Tennessee Oncology Navigates Clinical Pathway Challenges and Advancements: Dr Edward Arrowsmith

Hayden E. Klein

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.

Cancer awareness ribbons | SewcreamStudio - stock.adobe.com

January 8th 2024

Cancer Detection Rates Dropped Due to COVID-19 Disruptions, Study Finds

Cancer incidence fell by 8.7% across all cancer sites during the first year of the pandemic, according to a new study.

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

January 6th 2024

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

Pearl Steinzor Rose McNulty

Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

January 3rd 2024

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

Brooke McCormick

Amy Laughlin, MD, MSHP, of Orlando Health commented on at-home cancer care costs and shared her predictions on how at-home cancer care will evolve.

Dr Kathi Mooney

January 3rd 2024

Dr Kathi Mooney Discusses Improving Patients' Quality of Life Through Technology

Brooke McCormick

Kathi Mooney, PhD, RN, FAAN, of the University of Utah, discussed technologies she and her team developed to help improve the quality of life of patients with cancer and their families.

Highlights From ASCO 2023

January 3rd 2024

ICYMI: Highlights From ASCO 2023

The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.

The top 5 Institute for Value-Based Medicine content of 2023

December 27th 2023

Top 5 Content From Institute for Value-Based Medicine® Events in 2023

Laura Joszt, MA

In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.

The Top 5 Oncology Articles of 2023

December 22nd 2023

Top 5 Most-Read Oncology Articles of 2023

Our most-read oncology content of 2023 included meeting coverage, research on an algorithm using patient-reported outcomes to predict hospital visits, and the launch of an National Comprehensive Cancer Network pilot project aiming to measure health equity.

Global-vegefox.com-stock.adobe.com

December 21st 2023

New Study Reveals Global Disparities in Access to Multiple Myeloma Cell Therapies

Giuliana Grossi

“Unfortunately, limited access to these therapies worldwide appears to be a major challenge,” the researchers wrote.

...

5 6 7 8 9 10 11 12 13

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions